154 related articles for article (PubMed ID: 28141797)
1. A combination of low-dose bevacizumab and imatinib enhances vascular normalisation without inducing extracellular matrix deposition.
Schiffmann LM; Brunold M; Liwschitz M; Goede V; Loges S; Wroblewski M; Quaas A; Alakus H; Stippel D; Bruns CJ; Hallek M; Kashkar H; Hacker UT; Coutelle O
Br J Cancer; 2017 Feb; 116(5):600-608. PubMed ID: 28141797
[TBL] [Abstract][Full Text] [Related]
2. Dual targeting of Angiopoetin-2 and VEGF potentiates effective vascular normalisation without inducing empty basement membrane sleeves in xenograft tumours.
Coutelle O; Schiffmann LM; Liwschitz M; Brunold M; Goede V; Hallek M; Kashkar H; Hacker UT
Br J Cancer; 2015 Feb; 112(3):495-503. PubMed ID: 25562438
[TBL] [Abstract][Full Text] [Related]
3. Pretreatment with VEGF(R)-inhibitors reduces interstitial fluid pressure, increases intraperitoneal chemotherapy drug penetration, and impedes tumor growth in a mouse colorectal carcinomatosis model.
Gremonprez F; Descamps B; Izmer A; Vanhove C; Vanhaecke F; De Wever O; Ceelen W
Oncotarget; 2015 Oct; 6(30):29889-900. PubMed ID: 26375674
[TBL] [Abstract][Full Text] [Related]
4. Anti-VEGF therapy induces ECM remodeling and mechanical barriers to therapy in colorectal cancer liver metastases.
Rahbari NN; Kedrin D; Incio J; Liu H; Ho WW; Nia HT; Edrich CM; Jung K; Daubriac J; Chen I; Heishi T; Martin JD; Huang Y; Maimon N; Reissfelder C; Weitz J; Boucher Y; Clark JW; Grodzinsky AJ; Duda DG; Jain RK; Fukumura D
Sci Transl Med; 2016 Oct; 8(360):360ra135. PubMed ID: 27733559
[TBL] [Abstract][Full Text] [Related]
5. Tumour-infiltrating neutrophils counteract anti-VEGF therapy in metastatic colorectal cancer.
Schiffmann LM; Fritsch M; Gebauer F; Günther SD; Stair NR; Seeger JM; Thangarajah F; Dieplinger G; Bludau M; Alakus H; Göbel H; Quaas A; Zander T; Hilberg F; Bruns CJ; Kashkar H; Coutelle O
Br J Cancer; 2019 Jan; 120(1):69-78. PubMed ID: 30377339
[TBL] [Abstract][Full Text] [Related]
6. Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model.
Iwai T; Sugimoto M; Harada S; Yorozu K; Kurasawa M; Yamamoto K
Oncol Rep; 2016 Aug; 36(2):626-32. PubMed ID: 27350037
[TBL] [Abstract][Full Text] [Related]
7. (99)mTc-(CO)(3) His-annexin A5 micro-SPECT demonstrates increased cell death by irinotecan during the vascular normalization window caused by bevacizumab.
Vangestel C; Van de Wiele C; Van Damme N; Staelens S; Pauwels P; Reutelingsperger CP; Peeters M
J Nucl Med; 2011 Nov; 52(11):1786-94. PubMed ID: 22045708
[TBL] [Abstract][Full Text] [Related]
8. S0502: A SWOG Phase III Randomized Study of Imatinib, With or Without Bevacizumab, in Patients With Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors.
Blanke CD; Rankin C; Corless C; Eary JF; Mulder K; Okuno SH; George S; Heinrich M
Oncologist; 2015 Dec; 20(12):1353-4. PubMed ID: 26576593
[TBL] [Abstract][Full Text] [Related]
9. Imatinib increases oxygen delivery in extracellular matrix-rich but not in matrix-poor experimental carcinoma.
Burmakin M; van Wieringen T; Olsson PO; Stuhr L; Åhgren A; Heldin CH; Reed RK; Rubin K; Hellberg C
J Transl Med; 2017 Feb; 15(1):47. PubMed ID: 28231806
[TBL] [Abstract][Full Text] [Related]
10. Effects of convection-enhanced delivery of bevacizumab on survival of glioma-bearing animals.
Wang W; Sivakumar W; Torres S; Jhaveri N; Vaikari VP; Gong A; Howard A; Golden EB; Louie SG; Schönthal AH; Hofman FM; Chen TC
Neurosurg Focus; 2015 Mar; 38(3):E8. PubMed ID: 25727230
[TBL] [Abstract][Full Text] [Related]
11. Microvessel density and endothelial cell proliferation levels in colorectal liver metastases from patients given neo-adjuvant cytotoxic chemotherapy and bevacizumab.
Eefsen RL; Engelholm L; Willemoe GL; Van den Eynden GG; Laerum OD; Christensen IJ; Rolff HC; Høyer-Hansen G; Osterlind K; Vainer B; Illemann M
Int J Cancer; 2016 Apr; 138(7):1777-84. PubMed ID: 26510166
[TBL] [Abstract][Full Text] [Related]
12. The VEGF rise in blood of bevacizumab patients is not based on tumor escape but a host-blockade of VEGF clearance.
Alidzanovic L; Starlinger P; Schauer D; Maier T; Feldman A; Buchberger E; Stift J; Koeck U; Pop L; Gruenberger B; Gruenberger T; Brostjan C
Oncotarget; 2016 Aug; 7(35):57197-57212. PubMed ID: 27527865
[TBL] [Abstract][Full Text] [Related]
13. Molecular profiling of cetuximab and bevacizumab treatment of colorectal tumours reveals perturbations in metabolic and hypoxic response pathways.
Greening DW; Lee ST; Ji H; Simpson RJ; Rigopoulos A; Murone C; Fang C; Gong S; O'Keefe G; Scott AM
Oncotarget; 2015 Nov; 6(35):38166-80. PubMed ID: 26517691
[TBL] [Abstract][Full Text] [Related]
14. Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature.
Pohl M; Werner N; Munding J; Tannapfel A; Graeven U; Nickenig G; Schmiegel W; Reinacher-Schick A
Z Gastroenterol; 2011 Oct; 49(10):1398-406. PubMed ID: 21964893
[TBL] [Abstract][Full Text] [Related]
15. Anti-stromal therapy with imatinib inhibits growth and metastasis of gastric carcinoma in an orthotopic nude mouse model.
Sumida T; Kitadai Y; Shinagawa K; Tanaka M; Kodama M; Ohnishi M; Ohara E; Tanaka S; Yasui W; Chayama K
Int J Cancer; 2011 May; 128(9):2050-62. PubMed ID: 21387285
[TBL] [Abstract][Full Text] [Related]
16. Functional evaluation of therapeutic response of HCC827 lung cancer to bevacizumab and erlotinib targeted therapy using dynamic contrast-enhanced and diffusion-weighted MRI.
Chen YF; Yuan A; Cho KH; Lu YC; Kuo MY; Chen JH; Chang YC
PLoS One; 2017; 12(11):e0187824. PubMed ID: 29121075
[TBL] [Abstract][Full Text] [Related]
17. Integration of novel agents in the treatment of colorectal cancer.
Iqbal S; Lenz HJ
Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
[TBL] [Abstract][Full Text] [Related]
18. Effect of yeast-derived beta-glucan in conjunction with bevacizumab for the treatment of human lung adenocarcinoma in subcutaneous and orthotopic xenograft models.
Zhong W; Hansen R; Li B; Cai Y; Salvador C; Moore GD; Yan J
J Immunother; 2009 Sep; 32(7):703-12. PubMed ID: 19561538
[TBL] [Abstract][Full Text] [Related]
19. VEGF-ablation therapy reduces drug delivery and therapeutic response in ECM-dense tumors.
Röhrig F; Vorlová S; Hoffmann H; Wartenberg M; Escorcia FE; Keller S; Tenspolde M; Weigand I; Gätzner S; Manova K; Penack O; Scheinberg DA; Rosenwald A; Ergün S; Granot Z; Henke E
Oncogene; 2017 Jan; 36(1):1-12. PubMed ID: 27270432
[TBL] [Abstract][Full Text] [Related]
20. Combination of anti-angiogenic therapies reduces osteolysis and tumor burden in experimental breast cancer bone metastasis.
Bachelier R; Confavreux CB; Peyruchaud O; Croset M; Goehrig D; van der Pluijm G; Clézardin P
Int J Cancer; 2014 Sep; 135(6):1319-29. PubMed ID: 24615579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
